Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders.
Pesu
Marko
M
Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA. pesum@mail.nih.gov
O'Shea
John
J
Hennighausen
Lothar
L
Silvennoinen
Olli
O
D006801:Humans; D053614:Janus Kinase 2; D008958:Models, Molecular; D009196:Myeloproliferative Disorders / Q000235:genetics* / Q000503:physiopathology*; D017354:Point Mutation; D017434:Protein Structure, Tertiary; D011505:Protein-Tyrosine Kinases / Q000737:chemistry / Q000235:genetics* / Q000502:physiology*; D011518:Proto-Oncogene Proteins / Q000737:chemistry / Q000235:genetics* / Q000502:physiology*
D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2